• Explore /
  • Poster
  • / Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.

Abstract Poster

Authors

null

Nancy L. Bartlett

Washington University School of Medicine, St. Louis, MO

Nancy L. Bartlett , Christopher A. Yasenchak , Khaleel K. Ashraf , William N. Harwin , James Michael Orcutt , Philip Kuriakose , Pier Luigi Zinzani , Adrija Mamidipalli , Keenan Fenton , Consuelo Glenn , Grzegorz S. Nowakowski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04404283

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7559)

DOI

10.1200/JCO.2022.40.16_suppl.7559

Abstract #

7559

Poster Bd #

212

Abstract Disclosures

Similar Posters

First Author: Nancy L. Bartlett

First Author: Jason Westin

First Author: Mehdi Hamadani

First Author: Grzegorz S. Nowakowski